SOURCE: Burrill & Company
SAN FRANCISCO, CA--(Marketwire - Nov 5, 2012) - Burrill & Company today announced an expansion of its growing investment banking business with the addition of veterans in institutional sales and investment banking.
"We are committed to helping our industry's leading life sciences companies succeed. Whether through global partnering, strategic M&A or capital raising with high quality funds, we can provide the expertise needed for success," says G. Steven Burrill, CEO of Burrill & Company, a diversified global financial services firm focused on the life sciences. "These new additions will further expand our expertise in serving these clients."
Kira Sheinerman joins Burrill & Company as a managing director to provide advisory services and raise capital for life sciences companies. Most recently she served as a managing director for healthcare investment banking at Rodman & Renshaw, where she raised more than $2 billion for small- and mid-sized biotechnology companies. Sheinerman comes to Burrill with experience working in industry, academia, and consulting. She holds an MBA from Baruch College, a Ph.D. in biomedical sciences from Mount Sinai School of Medicine, and a B.S. and M.S. in molecular biology from Kiev State University.
Ron Ree joins Burrill & Company as director of institutional sales. He most recently worked at Roth Capital Partners where he was focused on corporate access, institutional sales, and investment banking. Prior to that, he worked for Rodman & Renshaw, Needham, and Adams, Harkness & Hill. Earlier in his career, he also held positions at Vector Securities, Paine Webber, Kidder Peabody, and Hambrecht & Quist. Prior to his work in the investment business, Ree practiced veterinary medicine for six years in Minnesota and North Dakota. He earned his DVM degrees from the University of Minnesota College of Veterinary Medicine and B.A. and a pre-med degree from St. Olaf College.
"One of the key things we do for our clients is to help them raise awareness with the industry's leading investors. Whether it's an emerging company with an exciting new technology or an industry leader, providing access to our deep investor network is a tremendous asset to our clients. The addition of Kira and Ron is another step in further enhancing that network," says Stephen Hurly, CEO of Burrill Investment Banking. "Our industry is going through a significant transformation in access to capital. We are ensuring we evolve with the new landscape to ensure success for our clients."
About Burrill Investment Banking
Burrill Investment Banking provides life sciences companies with access to financial resources through global capital and a blend of complementary financial advisory services on public and private financings and cross-border transactions, including M&A, strategic partnerships, spinouts, and public and private capital raising. It provides companies enhanced access to public market investors through its Institutional Equities business. Our team has extensive experience and a comprehensive global network to help life sciences companies access capital and strategic partners to build their businesses.
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.